No Data
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Express News | UBS Group's Short Position in Shanghai Henlius Biotech Reduced to 0% on Dec 2 From 2.07% - HKEX
Announcement highlights | Insurers have raised their shareholding in brokerage stocks for the first time in nearly 5 years! New China Life Insurance has increased its shareholding in Haitong Sec; Meitu has liquidated its cryptos for a profit of nearly 80
In November, Country Garden achieved a contract sales amount of approximately 3.01 billion yuan attributable to the company's shareholders; chinares pharma's pharmaceutical commerce can issue a total of 15 billion yuan in asset-backed notes in installments.
Hong Kong stocks morning report on December 5: Most china concept stocks fell, Meitu cleared its crypto profits of about 0.571 billion yuan.
The latest Beige Book survey from the Federal Reserve shows a slight increase in economic activity in November. Federal Reserve Chairman Powell stated that the Fed can remain cautious when looking for the neutral interest rate. President Trump selected digital assets advocate Paul Atkins to be the chairman of the U.S. Securities and Exchange Commission, causing a surge in cryptocurrencies and related stocks. The three major U.S. stock indexes hit record highs on Wednesday, while most popular China concept stocks fell.
Henlius (02696.HK): The application for a 1b/2 phase clinical trial for the injection of HLX43 (targeting PD-L1 antibody - new DNA topoisomerase I inhibitor conjugate) as a monotherapy or in combination therapy for advanced/metastatic solid tumors has bee
Gracell announced on December 4th that Henlius (02696.HK) recently received approval from the National Medical Products Administration (NMPA) for the application of HLX43 (a PD-L1 targeting antibody - a novel DNA topoisomerase I inhibitor conjugate drug) for monotherapy or combination therapy in phase 1b/2 clinical trials for advanced/metastatic solid tumors. The company plans to conduct clinical trials of the product for the relevant indications in China (excluding Hong Kong, Macao, and Taiwan) once the conditions are met. HLX43 was obtained by the company from Yilian Biomedical in Suzhou in November 2022.
